Last edition
News about "bispecific antibodies "
WuXi Biologics Secures South Korea GMP Certification for Key Manufacturing Facilities
The South Korea GMP Certification from the Ministry of Food and Drug Safety strengthens WuXi Biologics’ end-to-end capabilities for commercial production of complex biologics, including cancer therapies.
Bispecific Antibodies | 23/04/2026 | By News Bureau
BioMed X Launches First Research Team in France to Advance AI-Driven Antibody Design
BioMed X launches AI-focused antibody research team in France, aiming to accelerate development of next-generation biologic therapies for cancer and immune diseases.
Bispecific Antibodies | 21/04/2026 | By News Bureau
Earendil Labs and WuXi Biologics Partner on Bispecific Antibodies and ADCs
Under the agreement, WuXi Biologics will provide end-to-end development and manufacturing services to Earendil Labs, supporting faster regulatory timelines, reliable CMC execution, and scalable global clinical development.
Bispecific Antibodies | 13/03/2026 | By News Bureau | 114
Nona Biosciences and Valink Partner to Advance Biologics Discovery
Nona Biosciences and Valink Therapeutics have partnered to advance biologics discovery by combining Nona’s Harbour Mice fully human antibody technologies, including heavy chain-only antibodies, with Valink’s LiliumX discovery platform to generate and screen thousands of novel drug candidates.
Bispecific Antibodies | 18/12/2025 | By News Bureau | 121
Allink Biotherapeutics Secures USD 42 Million Series A Financing Round
The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors.
Bispecific Antibodies | 02/12/2024 | By Aishwarya | 210
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy